Switch to Yanping Hu's research page...

2003

1. Hu Y, Bally M, Dragowska WH, Mayer L. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol Cancer Ther 2(7):641-9. (2003).
    [View Abstract - PubMed 12883037]  Request Paper

2. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 9(7):2826-36. (2003).
    [View Abstract - PubMed 12855663]  Request Paper

3. Hu YP, Haq B, Carraway KL, Savaraj N, Lampidis TJ. Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells. Biochem Pharmacol 65(9):1419-25. (2003).
    [View Abstract - PubMed 12732353]  Request Paper

4. Lopes de Menezes DE, Hu Y, Mayer LD. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice. J Exp Ther Oncol 3(2):72-82. (2003).
    [View Abstract - PubMed 12822513]  Request Paper

5. Shabbits JA, Hu Y, Mayer LD. Tumor chemosensitization strategies based on apoptosis manipulations. Mol Cancer Ther 2(8):805-13. (2003).
    [View Abstract - PubMed 12939471]  Request Paper

2001

6. Hu Y, Dragowska WH, Wallis A, Duronio V, Mayer L. Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer. Breast Cancer Res Treat 70(1):11-20. (2001).
    [View Abstract - PubMed 11767000]  Request Paper

7. Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 40(18):5542-7. (2001).
    [View Abstract - PubMed 11331019]  Request Paper

2000

8. Hu Y, Moraes CT, Savaraj N, Priebe W, Lampidis TJ. Rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs. Biochem Pharmacol 60(12):1897-905. (2000).
    [View Abstract - PubMed 11108806]  Request Paper

9. Krishan A, Sridhar KS, Mou C, Stein WD, Lyubimov E, Hu YP, Fernandez H. Synergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin. Clin Cancer Res 6(4):1508-17. (2000).
    [View Abstract - PubMed 10778983]  Request Paper

1997

10. Bennis S, Faure P, Chapey C, Hu YP, Fourche J, El Yamani J, Robert J. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin. Anticancer Drugs 8(6):610-7. (1997).
     [View Abstract - PubMed 9300576]  Request Paper

11. Hu YP, Robert J. Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance. J Cancer Res Clin Oncol 123(4):201-10. (1997).
     [View Abstract - PubMed 9177492]  Request Paper

1996

12. Hu YP, Jarillon S, Dubernet C, Couvreur P, Robert J. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemother Pharmacol 37(6):556-60. (1996).
     [View Abstract - PubMed 8612309]  Request Paper

13. Hu YP, Pourquier P, Doignon F, Crouzet M, Robert J. Effects of modulators of multidrug resistance on the expression of the MDR1 gene on human KB cells in culture. Anticancer Drugs 7(7):738-44. (1996).
     [View Abstract - PubMed 8949984]  Request Paper

1995

14. Hu YP, Henry-Toulme N, Robert J. Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells. Eur J Cancer 31A(3):389-94. (1995).
     [View Abstract - PubMed 7786607]  Request Paper

15. Hu YP, Robert J. Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies. Biochem Pharmacol 50(2):169-75. (1995).
     [View Abstract - PubMed 7632160]  Request Paper